Literature DB >> 19645050

The lifetime prevalence of traumatic events and posttraumatic stress disorder in the Netherlands.

Giel-Jan de Vries1, Miranda Olff.   

Abstract

Little information exists on the lifetime prevalence of traumatic events and posttraumatic stress disorder (PTSD) in the general population of the Netherlands. A national representative sample of 1087 adults aged 18 to 80 years was selected using random digit dialing and then surveyed by telephone using the Composite International Diagnostic Interview (CIDI) to determine the prevalence of trauma and DSM-IV PTSD. The lifetime prevalence of any potential trauma was 80.7%, and the lifetime prevalence of PTSD was 7.4%. Women and younger persons showed higher risk of PTSD. It was concluded that PTSD is a fairly common disorder and exposure to trauma is high throughout the population. Unexpectedly, prevalence rates resemble those found in the United States and are higher than in several other European countries.

Entities:  

Mesh:

Year:  2009        PMID: 19645050     DOI: 10.1002/jts.20429

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  86 in total

1.  Characteristics of polytrauma patients with posttraumatic stress disorder in a level 1 trauma center.

Authors:  B E Kreis; N J Y Castano; W E Tuinebreijer; L C A Hoogenboom; S A G Meylaerts; S J Rhemrev
Journal:  Eur J Trauma Emerg Surg       Date:  2011-04-29       Impact factor: 3.693

2.  Determinants of the development of post-traumatic stress disorder, in the general population.

Authors:  Marc Perrin; Caroline L Vandeleur; Enrique Castelao; Stéphane Rothen; Jennifer Glaus; Peter Vollenweider; Martin Preisig
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-03       Impact factor: 4.328

3.  The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Risë B Goldstein; Sharon M Smith; S Patricia Chou; Tulshi D Saha; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-04-22       Impact factor: 4.328

Review 4.  Epidemiology of posttraumatic stress disorder: prevalence, correlates and consequences.

Authors:  Lukoye Atwoli; Dan J Stein; Karestan C Koenen; Katie A McLaughlin
Journal:  Curr Opin Psychiatry       Date:  2015-07       Impact factor: 4.741

Review 5.  A consideration of select pre-trauma factors as key vulnerabilities in PTSD.

Authors:  Jessica Bomyea; Victoria Risbrough; Ariel J Lang
Journal:  Clin Psychol Rev       Date:  2012-07-20

6.  Trauma, PTSD, and complex PTSD in the Republic of Ireland: prevalence, service use, comorbidity, and risk factors.

Authors:  Philip Hyland; Frédérique Vallières; Marylène Cloitre; Menachem Ben-Ezra; Thanos Karatzias; Miranda Olff; Jamie Murphy; Mark Shevlin
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-07-06       Impact factor: 4.328

Review 7.  Prospects for the pharmacological prevention of post-traumatic stress in vulnerable individuals.

Authors:  Sarah A Ostrowski; Douglas L Delahanty
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 8.  From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders.

Authors:  Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin
Journal:  Neurobiol Learn Mem       Date:  2013-12-07       Impact factor: 2.877

9.  Effects of intranasal oxytocin on amygdala reactivity to emotional faces in recently trauma-exposed individuals.

Authors:  Jessie L Frijling; Mirjam van Zuiden; Saskia B J Koch; Laura Nawijn; Dick J Veltman; Miranda Olff
Journal:  Soc Cogn Affect Neurosci       Date:  2015-09-17       Impact factor: 3.436

10.  Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in Posttraumatic Stress Disorder.

Authors:  Saskia B J Koch; Mirjam van Zuiden; Laura Nawijn; Jessie L Frijling; Dick J Veltman; Miranda Olff
Journal:  Neuropsychopharmacology       Date:  2016-01-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.